CYP19A1 Genetic Polymorphisms rs4646 and Osteoporosis in Patients Treated with Aromatase Inhibitor-Based Adjuvant Therapy.

Journal: The Eurasian journal of medicine
Published Date: Jul 7, 2015

Abstract

OBJECTIVE: Third-generation aromatase inhibitors (AI) are potent suppressors of aromatase activity. The aim of this study was to measure the incidence of adverse effects in breast cancer patients treated with AI-based adjuvant therapy and the relationship with the CYP19A1 genotypes.

Authors

  • Federica Mazzuca
    Department of Clinical Oncology, Sant'Andrea Hospital, School of Medicine and Psychology, University of Rome La Sapienza, Rome, Italy.
  • Andrea Botticelli
    Department of Clinical Oncology, Sant'Andrea Hospital, School of Medicine and Psychology, University of Rome La Sapienza, Rome, Italy.
  • Eva Mazzotti
    Department of Emergency Medicine, Acıbadem University School of Medicine, İstanbul, Turkey.
  • Marco La Torre
    Department of General Surgery, Sant'Andrea Hospital, School of Medicine and Psychology, University of Rome La Sapienza, Rome, Italy.
  • Marina Borro
    Department of Advanced Molecular Diagnosis Unit (DiMA), Sant'Andrea Hospital Department of Medical-Surgical Sciences and Translational Medicine, Faculty of Medicine and Psychology, University of Rome La Sapienza, Rome, Italy.
  • Luca Marchetti
    Department of Clinical Oncology, Policlinico Umberto I, School of Medicine and Psychology, University of Rome La Sapienza, Rome, Italy.
  • Chiara Maddalena
    Department of Clinical Oncology, Sant'Andrea Hospital, School of Medicine and Psychology, University of Rome La Sapienza, Rome, Italy.
  • Giovanna Gentile
    Department of Advanced Molecular Diagnosis Unit (DiMA), Sant'Andrea Hospital Department of Medical-Surgical Sciences and Translational Medicine, Faculty of Medicine and Psychology, University of Rome La Sapienza, Rome, Italy.
  • Maurizio Simmaco
    Department of Advanced Molecular Diagnosis Unit (DiMA), Sant'Andrea Hospital Department of Medical-Surgical Sciences and Translational Medicine, Faculty of Medicine and Psychology, University of Rome La Sapienza, Rome, Italy.
  • Paolo Marchetti
    Department of Clinical Oncology, Sant'Andrea Hospital, School of Medicine and Psychology, University of Rome La Sapienza, Rome, Italy.

Keywords

No keywords available for this article.

External Resources

Popular Topics
Recent Journals